Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) has provided an update.
Qiagen has disclosed a voting rights announcement following notification from the Dutch regulator AFM that Goldman Sachs Group Inc. holds a 3.60% interest in the company’s share capital and voting rights through a mix of direct shareholdings, derivatives, and other financial instruments. The position, spread across various Goldman Sachs entities and including ordinary shares, call options, swaps, warrants and convertible bonds, underscores the continued interest of major global financial institutions in Qiagen’s equity, potentially influencing market perceptions of the stock’s liquidity and ownership structure, though Qiagen emphasizes it is not responsible for the accuracy of the AFM-filed data.
The most recent analyst rating on (QGEN) stock is a Hold with a $48.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
Qiagen N.V., based in Venlo, Netherlands, is a life sciences and molecular diagnostics company whose shares are listed on several European exchanges as well as the NYSE and Swiss markets. The company operates globally, providing sample and assay technologies for molecular testing across research, clinical and applied markets, and is widely held by international institutional investors.
Average Trading Volume: 1,196,106
Technical Sentiment Signal: Strong Buy
Current Market Cap: $9.81B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.